Monotherapy With Immune Checkpoint Blockade Improves Survival Outcomes in KRAS-Mutant but Not KRAS Wild-Type Metastatic Lung Adenocarcinoma: Validation From an Extended Swedish Cohort.

ABSTRACT:

Introduction

Immune checkpoint blockade (ICB) is a standard first-line treatment for stage IV NSCLC without actionable oncogenic alterations. KRAS mutations, prevalent in 30% to 40% lung adenocarcinomas (LUAD) in Western populations, currently lack targeted first-line therapies. This study aimed to assess the predictive value of KRAS mutations for clinical outcomes after distinct ICB regimens, validating our previous findings in a larger cohort with extended follow-up.

Methods

We conducted a retrospective multicenter study including consecutive stage IV LUAD patients (n = 424) treated with either ICB or platinum-doublet chemotherapy between 2016 and 2021 in Western Sweden. Patient demographics, tumor characteristics, treatment details, and survival outcomes wer

SUBMITTER: Eklund EA 

PROVIDER: S-EPMC12414821 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature